PINEHURST – FirstHealth Moore Regional Hospital has enrolled a patient in a clinical trial for a possible remedy for COVID-19, and is said to be the first place to do so.
A hospital spokesman refused to tell if the patient was from Richmond County. The trial reaches a mixed remedy regimen for COVID-19 that uses antiviral remdesivir, as well as a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, according to FirstHealthArray.
It is performed among adults hospitalized positive for COVID-19 in the United States, Mexico and 16 other countries on five continents. The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, sponsors and reverses the Phase 3 Trial, called Hospital Treatment with Anti-Coronavirus Immunoglobulin, or ITAC, according to a hospital release.
Gretchen Arnoczy, M. D. , an infectious disease doctor at FirstHealth, is the lead researcher in the Pinehurst trial.
“There is such a pressing desire to locate and effective remedies for COVID-19, and we feel privileged to participate in study activities aimed at providing remedies and responses to this crisis,” Arnoczy said in a statement.
FirstHealth has been the remdesivir to treat patients hospitalized with COVID-19 since May. The hospital also continues to treat patients with convalescent plasma. Remdesivir is a broad spectrum experimental antiviral discovered and developed through Gilead Sciences, Inc. in Host City, California.
The antibody solution tested in the trial is intravenous hyperimmune immunoglobulin anti-coronavirus, or hIVIG. The antibodies in the HIVIG coronavirus come from the liquid component of the blood, or plasma, donated through other healthy people who have recovered from COVID-19. These antibodies are highly purified and concentrated, so hIVIG anti-coronavirus consistently comprises several times more neutralizing antibodies than those discovered in the plasma of other people who have recovered from COVID-19.
“This is different from convalescence plasma in that the amount of antibodies is standardized, and the antibodies that are infused are known to neutralize the virus,” Arnoczy explained. ‘It was expected that, by giving other people with COVID-19, the ‘ready’ -to-use ‘antibodies at the onset of COVID-19 symptoms, before the framework reacts alone, may be only the herbal immune reaction of the framework to COVID-19 and patients can recover more temporarily and decrease the threat of serious illness and death.
Study participants will be randomly assigned to obtain HIVIG and remdesivir or placebo anti-coronavirus infusions and re-use them. Neither the participants nor the examination team will know who is receiving what remedy regimen.
For more data on the ITAC, ClinicalTrials. gov, NCT04546581 test.
For the Richmond County journal, subscribe to https://www. yourdailyjournal. com/subscribe. Contact Gavin Stone at 910-817-2673 or [email protected]
NC claim for damages in ‘chemicals forever’
County Crime Report, October 13